Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Invested Capital (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Invested Capital data on record, last reported at $776.9 million in Q3 2025.

  • For Q3 2025, Invested Capital rose 6.76% year-over-year to $776.9 million; the TTM value through Sep 2025 reached $776.9 million, up 6.76%, while the annual FY2024 figure was $1.1 billion, 66.39% up from the prior year.
  • Invested Capital reached $776.9 million in Q3 2025 per AMPH's latest filing, up from $757.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.1 billion in Q4 2024 and bottomed at $438.6 million in Q3 2021.
  • Average Invested Capital over 5 years is $623.5 million, with a median of $596.9 million recorded in 2022.
  • Peak YoY movement for Invested Capital: dropped 2.95% in 2021, then skyrocketed 66.39% in 2024.
  • A 5-year view of Invested Capital shows it stood at $453.9 million in 2021, then surged by 31.51% to $596.9 million in 2022, then grew by 8.47% to $647.4 million in 2023, then surged by 66.39% to $1.1 billion in 2024, then decreased by 27.89% to $776.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $776.9 million in Q3 2025, $757.5 million in Q2 2025, and $751.4 million in Q1 2025.